|
Post by mnholdem on Apr 9, 2018 7:18:49 GMT -5
Shoutbox (WC Wainwright conference)
mnholdem: Have a terrific day everyone! 1 minute ago x
majorwood: Great Job Mike C 1 minute ago x
mnholdem: I have to get to work so I'm closing the Shout Box. Discussions can continue in the WC Wainwright thread. 1 minute ago x
mnholdem: My assessment is that Mike Castagna presented a lot of info in a short time and did a decent job of presenting a case for investing in MannKind Corporation. 2 minutes ago x
mnholdem: Applause indicated quite a few attendees...before the sound kicked out and the operation announced "end of presentation". 3 minutes ago x
mnholdem: End of presentation. "I'll be here to answer more of your questions". 4 minutes ago x
mnholdem: Mike answered that the old label didn't let them answer that, the new label does. 5 minutes ago x
mnholdem: Question asked about speed of Afrezza. 5 minutes ago x
mnholdem: Taking question 6 minutes ago x
mnholdem: 5 Year Revenue Drivers 6 minutes ago x
mnholdem: Checklist of Near Term Milestones and Key Events 7 minutes ago x
mnholdem: Our company needs to rebuild credibility with investors...checklist. 8 minutes ago x
mnholdem: Reduced and restructure debt. 9 minutes ago x
mnholdem: Receptor Life Sciences update 10 minutes ago x
mnholdem: Pulmonary Hypertension trial sost: "less than $20 million to get to launch" 10 minutes ago x
mnholdem: If you're not publishing and presenting data, you're not relevant. 12 minutes ago x
reality: I just have one question: If 98% of patients don't know about it how are they going to demand it and how will doctors prescribe it? 12 minutes ago x
mnholdem: We're going to try to prove that 2-unit cartridge isn't necessary (pediatric trial) 13 minutes ago x
cjm18: Upfront!!! 14 minutes ago x
mnholdem: Talking about clinical programs now. 14 minutes ago x
mnholdem: Upfront $ and future royalties 15 minutes ago x
mnholdem: Working in markets: India, China and Mexico 15 minutes ago x
mnholdem: He's singing Sport's song. :-) 15 minutes ago x
mnholdem: We know patients want the drug once they learn about it. We just need doctors to prescribe and patient demand. 16 minutes ago x
mnholdem: 98% of people with diabetes doesn't know Afrezza exists. 16 minutes ago x
mnholdem: Targeted markets: "We already have 40% market share with some doctors." 17 minutes ago x
mnholdem: Fixed costs. Every 1% market share will translate into $70-$100 "in NET sales" - Mike 18 minutes ago x
mnholdem: Coverage: Value story vs rebates 20 minutes ago x
mnholdem: Driving Demand: LEADERSHIP, IMPROVE ACCESS, MARKETING CAMPAIGNS, PATIENT SUPPORT, NEW PACKAGING 20 minutes ago x
mnholdem: Uniqueness, efficacy, safety and dosing 21 minutes ago x
mnholdem: Mike is explaining what they are now telling doctors. 22 minutes ago x
mnholdem: 35% reduction 23 minutes ago x
mnholdem: 35% in severe hypos...is he talking about STAT? 23 minutes ago x
mnholdem: Mealtime insulin market has not shifted in many years...ripe for disruption. 24 minutes ago x
mnholdem: "adding Afrezza earlier is much easier for the physician" than introducing injected insulin. 25 minutes ago x
cjm18: I missed the first 30 seconds about the capital raise. Something about the economy? 26 minutes ago x
nxc2: switching to html5 worked 27 minutes ago x
cjm18: Refresh the page. 27 minutes ago x
mnholdem: Try hitting refresh or click "change to a different browser". 27 minutes ago x
mnholdem: Talking about David Kendall bringing "credibility" to the company. 28 minutes ago x
nxc2: I hear nothing and on slide 1 did it start? 28 minutes ago x
mnholdem: Listening to Mike now. 30 minutes ago x
mnholdem: Shoutbox for H C Wainwright Conference is open. Webcast states "Presentation starts in 3 minutes."
|
|
|
Post by mnholdem on Apr 9, 2018 7:21:44 GMT -5
Mike confirmed that they are working in India, China and Mexico markets and deals are forthcoming with upfront payments and future royalties.
|
|
|
Post by Clement on Apr 9, 2018 7:40:46 GMT -5
At the very beginning, what did Mike C say about the capital raise / dilution last week?
|
|
|
Post by cjm18 on Apr 9, 2018 7:42:55 GMT -5
Mike confirmed that they are working in India, China and Mexico markets and deals are forthcoming with upfront payments and future royalties.
One seemed like a done deal (signed term sheet). Maybe a second too. Recording is up. investors.mannkindcorp.com/webcasts#Blamed capital raise on equity markets and economy.
|
|
|
Post by boca1girl on Apr 9, 2018 8:02:08 GMT -5
At the very beginning, what did Mike C say about the capital raise / dilution last week? I heard: ...they were concerned about the volatility in the market so they decided to go forward now with a capital raise because capital markets can close up. He talked about the amount of money raised and the potential of another $33m if warrants are exercised. But before he said the above statements he acknlowdeged the concern from current shareholders about dilution and said he would only do what was essential for operations.
|
|
|
Post by mnholdem on Apr 9, 2018 8:04:41 GMT -5
At the very beginning, what did Mike C say about the capital raise / dilution last week? He mentioned it at the very beginning as he gave a quick overview of what he would be presenting, then later he mentioned it while showing the 2018 forecast revenue slide which also listed a forecasted $80-$100 spend for 2018. Mike stated that MannKind had $58 million cash/equivalents on Jan 1 and raised approximately $28 million last week.
|
|
|
Post by mango on Apr 9, 2018 8:07:16 GMT -5
At the very beginning, what did Mike C say about the capital raise / dilution last week? He mentioned it at the very beginning as he gave a quick overview of what he would be presenting, then later he mentioned it while showing the 2018 forecast revenue slide which also listed a forecasted $80-$100 spend for 2018. Mike stated that MannKind had $58 million cash/equivalents on Jan 1 and raised approximately $28 million last week.
Slide was redundant but was anything new spoken about RLS?
|
|
|
Post by mnholdem on Apr 9, 2018 8:13:30 GMT -5
No. Same slide showing comparisons to current brands.
|
|
|
Post by peppy on Apr 9, 2018 8:58:40 GMT -5
Mike is throwing out the insulin fun facts on the webcast replay. there are 6 million people on basal insulin in the USA. No wonder the tuejeo guy is mowing his lawn in circles dancing. From Sayhey: Question: People with type 2 are usually started out on a basal insulin. AM: Well, that is medically incorrect. Starting a type 2 on basal insulin is done today because current prandial insulin products are not physically sound so they are delayed about as long as they can be. Lantus has been so successful as the first insulin used in type 2 because of the problems with current prandial products. www.diabetesincontrol.com/an-exclusive-interview-with-al-mann-founder-and-ceo-mannkind-corp/This one is good too Question - Aren't most Type 2s currently treated with a basal insulin only, instead of mealtime dosing? Al: Yes, but that's the wrong way around. The correct therapy should be a good prandial insulin and not long-term insulin — Afrezza in particular because it turns off glucose production and delivery from the liver. Our latest trials of 600 patients are showing even more significant benefits from the product than our original trials; the most recent trial appears to show that this should replace frontline treatment for all Type 2 patients. www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mann#2The target market is huge. Hello vietnam.
|
|
|
Post by centralcoastinvestor on Apr 9, 2018 9:08:09 GMT -5
Thanks mnholdem for listening in and providing commentary. I totally had the wrong time in my head for this event. I think it is good news that Mike C. is watching the markets and thinking ahead on financing. Mike C. is right that the markets are very crazy now and MannKind cannot afford to be locked out of additional financing when needed. Based on Mike C. reasoning, I believe they did the right thing in raising the $28 million when they could. If the market continues to be this wild, those funding sources could dry up.
|
|
|
Post by peppy on Apr 9, 2018 9:10:45 GMT -5
Events are setting up, MNKD could be the big presenter at the ADA. STAT. clinicaltrials.gov/ct2/show/NCT03143816More from Mike two players have 98% market share. 7 out of ten people on meal time insulin are not at goal. Mike C. "Not a question of will Afrezza be successful, but a question of when." Demand important. Blue tooth available for training. Amphstar. We working with India, china, two term sheets, something signed this quarter.
|
|
|
Post by digger on Apr 9, 2018 9:43:57 GMT -5
Was there any mention about getting improved insurance coverage. Nothing showed up in the slides.
|
|
|
Post by mnholdem on Apr 9, 2018 9:48:33 GMT -5
Only Mike's mention that they are marketing/presenting payers with a "value story" vs "rebate".
|
|
|
Post by digger on Apr 9, 2018 9:56:40 GMT -5
Only Mike's mention that they are marketing/presenting payers with a "value story" vs "rebate". I'm not sure how to interpret that. Is he saying he's trying to avoid price competition with the BPs?
|
|
|
Post by peppy on Apr 9, 2018 10:34:15 GMT -5
Only Mike's mention that they are marketing/presenting payers with a "value story" vs "rebate". I'm not sure how to interpret that. Is he saying he's trying to avoid price competition with the BPs? Difficult to interpret.
|
|